Columbia Labs Gets Positive Results in Buccal Phase 3
Columbia Laboratories
(COB)
said its buccal tablet raised blood-testosterone levels more effectively than a patch-delivered system in a phase 3 trial.
The company said the results will be presented to the Food and Drug Administration in December when the company seeks a preliminary new drug application for the drug, which treats a condition in which the testes produce inadequate hormone levels.
Scroll to Continue
TheStreet Recommends
The trial was conducted on 66 men and compared the tablets to Andropatch, a
SmithKline Beecham
(SBH) - Get Sally Beauty Holdings Inc. (Name to be changed from Holdings Inc.) Report
product that is licensed in the U.K.
